CN105792831A - 用于治疗纤维化癌症的方法 - Google Patents

用于治疗纤维化癌症的方法 Download PDF

Info

Publication number
CN105792831A
CN105792831A CN201480062728.5A CN201480062728A CN105792831A CN 105792831 A CN105792831 A CN 105792831A CN 201480062728 A CN201480062728 A CN 201480062728A CN 105792831 A CN105792831 A CN 105792831A
Authority
CN
China
Prior art keywords
sap
treatment
myelofibrosis
agonist
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480062728.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·布鲁恩
E·特里胡
M·鲁普赫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promedior Inc
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc filed Critical Promedior Inc
Priority to CN202111292205.8A priority Critical patent/CN114053395A/zh
Publication of CN105792831A publication Critical patent/CN105792831A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480062728.5A 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法 Pending CN105792831A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111292205.8A CN114053395A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US61/888,269 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US61/992,807 2014-05-13
US201462004836P 2014-05-29 2014-05-29
US201462004828P 2014-05-29 2014-05-29
US62/004,828 2014-05-29
US62/004,836 2014-05-29
PCT/US2014/059699 WO2015054390A1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111292205.8A Division CN114053395A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Publications (1)

Publication Number Publication Date
CN105792831A true CN105792831A (zh) 2016-07-20

Family

ID=52813618

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480062728.5A Pending CN105792831A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法
CN202111292205.8A Pending CN114053395A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111292205.8A Pending CN114053395A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Country Status (10)

Country Link
US (2) US11020451B2 (https=)
EP (2) EP3718558A1 (https=)
JP (2) JP6636914B2 (https=)
CN (2) CN105792831A (https=)
AU (2) AU2014331954B2 (https=)
CA (1) CA2926418A1 (https=)
ES (1) ES2784234T3 (https=)
PL (1) PL3054959T3 (https=)
RU (2) RU2718056C2 (https=)
WO (1) WO2015054390A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108715865A (zh) * 2018-05-28 2018-10-30 福建师范大学 用于提高细胞转染效率的试剂组合物
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
CN115335047A (zh) * 2020-01-28 2022-11-11 拉结尔治疗有限公司 用于治疗血管脂肪瘤的组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792831A (zh) 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
CA2983004A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
KR20200139721A (ko) * 2018-03-28 2020-12-14 블레이드 테라퓨틱스, 인크. 섬유성 질환을 치료하는 방법
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2020219423A1 (en) * 2019-04-25 2020-10-29 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
KR102725907B1 (ko) * 2021-11-25 2024-11-04 성균관대학교산학협력단 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법
KR20260016906A (ko) * 2023-03-17 2026-02-04 엠디엑스 메니지먼트 엘엘씨 요법의 유해효과를 개선하기 위한 조성물 및 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
CN101166539B (zh) * 2005-02-08 2012-01-04 得克萨斯大学体系董事会 用于治疗癌症的涉及mda-7的组合物和方法
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
HUE030269T2 (en) * 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
WO2009009034A2 (en) * 2007-07-06 2009-01-15 Promedior, Inc Methods and compositions useful in the treatment of mucositis
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
US20100266643A1 (en) 2009-04-01 2010-10-21 Willett W Scott Pulmonary and nasal delivery of serum amyloid p
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
US20130195861A1 (en) 2011-12-21 2013-08-01 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
CN105792831A (zh) 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
CA2983004A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108715865A (zh) * 2018-05-28 2018-10-30 福建师范大学 用于提高细胞转染效率的试剂组合物
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
CN115335047A (zh) * 2020-01-28 2022-11-11 拉结尔治疗有限公司 用于治疗血管脂肪瘤的组合物

Also Published As

Publication number Publication date
EP3718558A1 (en) 2020-10-07
EP3054959A4 (en) 2017-04-26
WO2015054390A1 (en) 2015-04-16
JP2016539087A (ja) 2016-12-15
RU2016117775A (ru) 2017-11-15
JP2020059752A (ja) 2020-04-16
JP6636914B2 (ja) 2020-01-29
US11020451B2 (en) 2021-06-01
PL3054959T3 (pl) 2020-07-13
RU2020111934A (ru) 2020-04-29
CN114053395A (zh) 2022-02-18
AU2020220139A1 (en) 2020-09-10
EP3054959B1 (en) 2020-01-08
ES2784234T3 (es) 2020-09-23
EP3054959A1 (en) 2016-08-17
US20160235812A1 (en) 2016-08-18
JP7140739B2 (ja) 2022-09-21
US20210322515A1 (en) 2021-10-21
CA2926418A1 (en) 2015-04-16
RU2016117775A3 (https=) 2018-07-27
RU2718056C2 (ru) 2020-03-30
AU2014331954B2 (en) 2020-05-21
AU2014331954A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
JP7140739B2 (ja) 線維性癌の治療方法
US20170002060A1 (en) Polynucleotides for the in vivo production of antibodies
JP2018512164A (ja) 骨髄増殖性障害を処置するための方法
WO2015105926A1 (en) Polynucleotides for the in vivo production of antibodies
ES2563748T3 (es) Derivados de amiloide P sérico y su preparación y uso
KR102810368B1 (ko) 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
US20160375145A1 (en) Etoposide and doxorubicin conjugates for drug delivery
EP4532771A2 (en) Compositions and methods for modulation of tumor suppressors and oncogenes
US11446376B2 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
CN103338782A (zh) 包含表面核仁素的多价合成配体和糖胺聚糖的组合物
KR20210010435A (ko) 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법
HK40069679A (en) Methods for treating fibrotic cancers
HK40039408A (en) Methods for treating fibrotic cancers
JP5393691B2 (ja) 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）
WO2014093870A2 (en) Use of c-c chemokine receptor type 7 (ccr7) inhibitors
HK1226660B (en) Methods for treating fibrotic cancers
HK1226660A1 (en) Methods for treating fibrotic cancers
WO2023196988A1 (en) Methods of use of mrnas encoding il-12

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160720

RJ01 Rejection of invention patent application after publication